证券代码：600201 证券简称：生物股份 公告编号：临 2025-052 金宇生物技术股份有限公司 关于拟回购注销 2023 年员工持股计划部分股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 金宇生物技术股份有限公司（以下简称"公司"）于 2025 年 8 月 19 日召开第 十二届董事会第三次会议，审议通过了《关于拟回购注销 2023 年员工持股计划部 分股票的议案》，拟对公司 2023 年员工持股计划（以下简称"本员工持股计划"） 离职的 3 名持有人尚未解锁的权益份额对应的标的股票数量 2.55 万股予以回购注 销。现将相关事项公告如下： （七）公司于 2025 年 5 月 28 日召开第十二届董事会第一次会议，审议通过了 《关于拟回购注销 2023 年员工持股计划部分股票的议案》。 二、本次回购注销的原因、数量及价格 根据《金宇生物技术股份有限公司 2023 年员工持股计划（草案修订稿）》和 《金宇生物技术股份有限公司 2023 年员工持股计划管理办法（修订稿）》的相关 规定，本次回购注销 ...

金宇生物技术股份有限公司2025 年半年度报告 三、 本半年度报告未经审计。 四、 公司负责人张翀宇、主管会计工作负责人李凯及会计机构负责人（会计主管人员）王利文 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司代码：600201 公司简称：生物股份 金宇生物技术股份有限公司 2025 年半年度报告 1 / 157 金宇生物技术股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 无 六、 前瞻性陈述的风险声明 √适用 □不适用 公司本报告涉及的公司未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺， 敬请投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 本公司已在 ...

Group 1 - The animal vaccine concept sector rose by 2.47%, ranking second among concept sectors, with 12 stocks increasing in value, including Shenlian Biological which hit a 20% limit up [1] - Leading stocks in the sector included Yongshun Biological, Xianfeng Holdings, and Biological Shares, which rose by 9.35%, 8.44%, and 2.92% respectively [1] - The sector experienced a net outflow of 0.31 billion yuan in main funds, with 12 stocks seeing net inflows, and five stocks receiving over 10 million yuan in net inflows [1] Group 2 - Shenlian Biological, with a net inflow of 20.03%, had the highest main fund inflow of 20 million yuan, followed by Biological Shares and Haizheng Pharmaceutical with net inflows of 17.39 million yuan and 17.13 million yuan respectively [2] - The top three stocks by main fund inflow ratio were Shenlian Biological at 6.76%, Ronioushan at 6.52%, and Zhongmu Shares at 5.23% [2][3] - Stocks such as Kanghua Biological, Jinhai Biological, and Dabeinong experienced significant net outflows, with Kanghua Biological seeing a decline of 1.35% and a net outflow of 47.41 million yuan [3]

智通财经APP讯，生物股份(600201.SH)发布2025年半年度报告，报告期内，公司实现营业收入6.2亿 元，同比增长1.28%。实现归属于上市公司股东的净利润6042.4万元，同比下降50.84%。实现归属于上 市公司股东的扣除非经常性损益的净利润3219.06万元，同比下降70.16%。基本每股收益0.06元。 ...

转自：证券时报 人民财讯8月19日电，生物股份(600201)8月19日晚间披露2025年半年报，公司上半年实现营业收入6.2亿 元，同比增长1.28%；归母净利润为6042.4万元，同比下降50.84%。基本每股收益0.06元。报告期内， 公司整体经营情况稳健，由于公司人用抗体药物研发费用及无形资产折旧摊销同比大幅增加，同时动保 行业竞争态势加剧，产品价格下降、毛利下滑。 ...

格隆汇8月19日丨生物股份(600201.SH)公布半年度报告，营业收入6.2亿元，同比增长1.28%，归属于上 市公司股东的净利润6042万元，同比下降50.84%，归属于上市公司股东的扣除非经常性损益的净利润 3219万元，同比下降70.16%。 ...

生物股份公告，2025年上半年营业收入6.2亿元，同比增长1.28%。净利润6042.4万元，同比下降 50.84%。 ...

证券之星消息，8月18日动物保健板块较上一交易日上涨2.2%，申联生物领涨。当日上证指数报收于 3728.03，上涨0.85%。深证成指报收于11835.57，上涨1.73%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688098 | 申联生物 | 12.83 | 20.02% | 13.27万 | 1.69 Z | | 300871 | 回盛生物 | 24.26 | 7.87% | 30.00万 | 7.20亿 | | 838275 | 驱动力 | 10.02 | 6.60% | 4.35万 | 4273.62万 | | 002141 | 贤丰控股 | 3.91 | 4.27% | 1 85.59万 | 3.38亿 | | 839729 | 永顺生物 | 9.95 | 3.65% | 3.11万 | 3066.40万 | | 871970 | 大禹生物 | 9.98 | 3.42% | 2.96万 | 2928.24万 | | 300119 | 瑞普生物 | ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights that a new round of price increases for pigs may gradually begin, with the African swine fever vaccine opening growth opportunities for the animal health sector [4][5] - The report emphasizes that the investment logic for live pigs is marginally improving, supported by both fundamental and policy factors, with recommendations for specific companies [5][31] Summary by Sections Weekly Observation - As of August 15, 2025, the national average price of live pigs is 13.73 CNY/kg, with a week-on-week increase of 0.06 CNY/kg but a year-on-year decrease of 7.44% [4][13] - The price premium for 150kg fat pigs over 120kg standard pigs is 0.28 CNY/kg, indicating a tightening supply [4][13] Weekly Market Performance (August 11-15) - The agricultural sector underperformed the market by 1.84 percentage points, with the agricultural index down 0.14% while the Shanghai Composite Index rose by 1.70% [6][35] - Key stocks that led the gains include COFCO Sugar (+41.04%), Shunli Biological (+13.97%), and Xiaoming Co. (+8.86%) [6][35] Price Tracking (August 11-15) - The average price of live pigs on August 15 is 13.76 CNY/kg, a slight increase from the previous week [6][46] - The average price of piglets is 28.87 CNY/kg, showing a decrease of 5.03% from the previous week [6][46] - The average price of white feathered chickens is 7.20 CNY/kg, with a week-on-week increase of 0.84% [6][51] Key News (August 11-15) - The central government allocated 1.146 billion CNY for agricultural disaster relief, supporting major grain-producing provinces [6][41]

Group 1 - The core viewpoint of the report emphasizes the importance of reviewing the full semi-annual report for a comprehensive understanding of the company's operational results, financial status, and future development plans [1] - The board of directors, supervisory board, and senior management guarantee the authenticity, accuracy, and completeness of the semi-annual report, taking legal responsibility for any false statements or omissions [1] - The report indicates that there are no profit distribution plans or capital reserve conversion plans approved by the board during the reporting period [2] Group 2 - The company has reported significant changes in the operating conditions during the reporting period, with a focus on matters that have had or are expected to have a major impact on the company's operations [2] - The controlling shareholder and its concerted actors have a high proportion of pledged and judicially frozen shares, with 77.15% of their shares being judicially frozen and 60.22% pledged as of June 30, 2025 [3] - The risk of judicial disposal of shares held by the controlling shareholder and its concerted actors is high due to multiple lawsuits and significant amounts involved, which could potentially lead to a change in actual control of the company [3]